About us
We are passionate about bringing the lab to the patient.
We are passionate about bringing the lab to the patient.
CEO
Guido has a strong, more than 15-year track record in life sciences (Pharming, Radboudumc, Sigmascreening, Gadeta, Bergman Clinics). He successfully closed several equity financing rounds, raised over €10M in non-dilutive funding (IK, EFRO, FP7, WBSO), and successfully closed multiple deals with big pharma. At Bergman Clinics he set up and led a state of the art treatment center with 5 operation rooms treating thousands of patients each year.
CSO
Waander has over 30 years of experience as an expert in coagulation. He successfully founded and managed a spin-off company for 5 years and generated over €3M in contract research revenues for the Radboudumc. He was an inventor on 7 patent applications, and was part of over 80 scientific publications, inamongst others NEJM, Lancet and Blood. He is a former member of the International Society on Thrombosis and Hemostasis Standardization, Sub Committee “Fibrinolysis”, and a previous member of the scientific advisory board for the Dutch Thrombosis Foundation.
COO
Bart has over 30 years’ experience in management of product development. He has worked on high tech systems, consumer products and medical devices, both within a corporate environment as well as consultant for corporate customers and smes’. He has founded a design and technology consultancy company that has grown into a leading European player in the development of professional products. He acts as part time COO for Enzyre.
Director IVD Development
Rachel is an experienced product developer with a demonstrated history of working in the medical device industry. Skilled in assay development; from (pre)feasibility, through verification & validation (V&V) to the actual registration of a product. She loves to solve complex challenges in a creative, innovative and responsible way. After her PhD in Immunology at the Dutch Vaccine Institute (now part of the National Institute for Public Health and the Environment), she joined Organon / MSD and worked on the development of a small molecules-based medicine for the treatment of Rheumatoid Arthritis. At Organon, she valued the importance of quality during development. In 2015, she joined Future Diagnostics as a project leader focusing on assay development for third parties. She, successfully, helped developing the Minicare system of Siemens (formally Philips).
By bringing the lab to the patient, we can improve the quality of life without increasing healthcare costs.
Save patients from bleeding to death.
Develop a handheld device that can run multiple assays in parallel to identify the cause of a bleed so therapy can be adjusted without delay.
Our team of experts is innovating near patient diagnostics with a focus on blood coagulation.
Enzyre is now preparing to raise an investment round. The proceeds will be used to (a) finalize the development of the ENZYPAD en ENZYCARD Hemophilia A, (b) manufacture the portable instrument & disposable, and (c) perform studies to obtain regulatory approval in EU & US. The product will be commercialized worldwide with support of our pharma partner. Interested candidate investors are encouraged to contact us at investors@enzyre.com.
Get involved
Enzyre BV
Transistorweg 5
6534-AT Nijmegen
The Netherlands
